The Breast
Volume 19, Issue 3 , Pages 192-197 , June 2010

Hypofractionated breast radiotherapy: Financial and economic consequences

References 

  1. Early Breast Cancer Trialists’ Collaborative Group. Favourable and unfavourable effects on long-term survival of radiotherapy for breast cancer an overview of the randomized trials. Lancet. 2000;355:1757–1770
  2. Early Breast Cancer Trialists’ Collaborative Group. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomized trials. Lancet. 2005;366:2087–2106
  3. Vrieling C, Collette L, Fourquet A, Hoogenraad WJ, Horiot JH, Jager JJ, et al. EORTC Radiotherapy and Breast Cancer Cooperative Groups The influence of patient, tumor and treatment factors on the cosmetic results after breast-conserving therapy in the EORTC ‘boost vs. no boost’ trial. Radiother Oncol. 2000;55(3):219–232
  4. Mannino M, Yarnold JR. Shorter fractionation schedules in breast cancer radiotherapy: clinical and economic implications. Eur J Cancer. 2009;45(5):730–731
  5. Bodenheimer T. High and rising health care costs. Part 2: technologic innovation. Ann Intern Med. 2005;142:932–937
  6. Perez CA, Kobeissi B, Smith BD, Fox S, Grigsby PW, Purdy JA, et al. Cost accounting in radiation oncology: a computer-based model for reimbursement. Int J Radiat Oncol Biol Phys. 1993;25:895–906
  7. Lievens Y, Van den Bogaert W, Kesteloot K. Activity-based costing: a practical model for cost calculation in radiotherapy. Int J Radiat Oncol Biol Phys. 2003;57:522–535
  8. Norlund A. Costs of radiotherapy. Acta Oncol. 2003;42:411–415
  9. Ploquin N, Dunscombe P. The cost of radiation therapy. Radiother Oncol. 2008;86:217–223
  10. Van de Werf E, Lievens Y, Verstraete J, Pauwels K, Van den Bogaert W. Time and motion study of radiotherapy delivery: economic burden of increased quality assurance and IMRT. Radiother Oncol. 2009;93(1):137–140
  11. Van de Werf E. Costs of radiotherapy: a benchmarking study using activity-based costing methodology. Thesis for obtaining the degree in Master of Health Care Management, vol. 8. Leuven: Katholieke Universiteit; 2009.
  12. Bentzen SM, Agrawal RK, Aird EG, Barrett JM, Barrett-Lee PJ, Bliss JM, et al. START Trialists’ Group The UK standardisation of breast radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomized trial. Lancet Oncol. 2008;9(4):331–341
  13. Bentzen SM, Agrawal RK, Aird EG, Barrett JM, Barrett-Lee PJ, Bliss JM, et al. START Trialists’ Group The UK standardisation of breast radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomized trial. Lancet. 2008;371(9618):1098–1107
  14. Whelan T, MacKenzie R, Julian J, Levine M, Shelley W, Grimard L, et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node-negative breast cancer. J Nat Cancer Inst. 2002;94(15):1143–1150
  15. Brunt AM, Sydenham M, Bliss J, Coles C, Gothard L, Harnett A et al. A 5-fraction regimen of adjuvant radiotherapy for women with early breast cancer: first analysis of the randomized UK FAST trial (ISRCTN62488883, CRUKE/04/015), abstract ECCO 15; 2009.
  16. Martin S, Mannino M, Rostom A, Tait D, Donovan E, Eagle S, et al. Acute toxicity and 2-year adverse effects of 30 Gy in five fractions over 15 days to whole breast after local excision of early breast cancer. Clin Oncol. 2008;20:502–505
  17. Suh WW, Pierce LJ, Vicini FA, Hayman JA. A cost comparison analysis of partial versus whole-breast irradiation after breast-conserving surgery for early-stage breast cancer. Int J Radiat Oncol Biol Phys. 2005;62(3):790–796
  18. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the panel on cost-effectiveness in health and medicine. J Am Med Ass. 1996;276:1253–1258
  19. Cleemput I, Neyt M, Thiry N, De Laet C, Leys M. Drempelwaarden voor kosteneffectiviteit in de gezondheidszorg. Health technology assessment (HTA). Brussel: Federaal Kenniscentrum voor de Gezondheidszorg (KCE); 2008;KCE reports 100A (D/2008/10.273/94)
  20. Weinstein MC. How much are Americans willing to pay for a quality-adjusted life year?. Med Care. 2008;46(4):343–345
  21. Lievens Y. Economic evaluation of post-operative radiotherapy in breast cancer: how a local treatment cost-effectively improves survival. Belgian J Med Oncol. 2008;2(5):284–287
  22. Liljegren G, Karlsson G, Bergh J, Holmberg L. The cost-effectiveness of routine postoperative radiotherapy after sector resection and axillary dissection for breast cancer stage I. Results from a randomized trial. Ann Oncol. 1997;8:757–763
  23. Hayman JA, Hillner BE, Harris JR, Weeks JA. Cost-effectiveness of routine radiation therapy following conservative surgery for early-stage breast cancer. J Clin Oncol. 1998;16(3):1022–1029
  24. Marks LB, Hardenbergh PH, Winer ET, Prosnitz LR. Assessing the cost-effectiveness of post-mastectomy radiotherapy. Int J Radiat Oncol Biol Phys. 1999;44(1):91–98
  25. Dunscombe P, Samant R, Roberts G. A cost-outcome analysis of adjuvant postmastectomy locoregional radiotherapy in premenopausal node-positive breast cancer patients. Int J Radiat Oncol Biol Phys. 2000;48(4):977–982
  26. Samant R, Dunscombe P, Roberts G. A cost-outcome analysis of adjuvant postmastectomy locoregional radiotherapy in high-risk postmenopausal breast cancer patients. Int J Radiat Oncol Biol Phys. 2001;50(5):1376
  27. Lee JH, Glick HA, Hayman JA, Solin JL. Decision-analytic model and cost-effectiveness evaluation of postmastectomy radiation therapy in high-risk premenopausal breast cancer patients. J Clin Oncol. 2002;20(11):2713–2725
  28. Suh WW, Hillner BE, Pierce LJ, Hayman JA. Cost-effectiveness of radiation therapy following conservative surgery for ductal carcinoma in situ of the breast. Int J Radiat Oncol Biol Phys. 2005;61(4):1054–1061
  29. Lievens Y, Kesteloot K, Van den Bogaert W. Economic consequence of local control with radiotherapy. Cost analysis of the internal mammary and medial supraclavicular lymph node irradiation in breast cancer. Int J Radiat Oncol Biol Phys. 2005;63(4):1122–1131
  30. Bentzen SM. High-tech in radiation oncology: should there be a ceiling?. Int J Radiat Oncol Biol Phys. 2004;58(2):320–330
  31. Sher DJ, Wittenberg E, Suh WW, Taghian AG, Punglia RS. Partial-breast irradiation versus whole-breast irradiation for early-stage breast cancer: a cost-effectiveness analysis. Int J Radiat Oncol Biol Phys. 2009;74(2):440–446
  32. Hayman JA, Hillner BE, Harris JR, Pierce LJ, Weeks JC. Cost-effectiveness of adding an electron-beam boost to tangential radiation therapy in patients with negative margins after conservative surgery for early-stage breast cancer. J Clin Oncol. 2000;18(2):287–295
  33. Bartelink H, Horiot JC, Poortmans PM, Struikmans H, Van den Bogaert W, Fourquet A, et al. Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. J Clin Oncol. 2007;25(22):3259–3265
  34. Cuzick J, Stewart H, Rutqvist L, Houghton J, Edwards R, Redmond C, et al. Cause-specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy. J Clin Oncol. 1994;12:447–453
  35. Marhin W, Wai E, Tyldesley S. Impact of fraction size on cardiac mortality in women treated with tangential radiotherapy for localized breast cancer. Int J Radiat Oncol Biol Phys. 2007;69(2):483–489

PII: S0960-9776(10)00057-3

doi: 10.1016/j.breast.2010.03.003

The Breast
Volume 19, Issue 3 , Pages 192-197 , June 2010

Article Tools

* Image Usage & Resolution